{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.46","upperLimit":"7.54","value":"5.87"},{"comment":"insufficient number of participants with events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"6.50"},{"comment":"insufficient number of participants with events","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"12"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"description":"Progression-free survival (PFS) will be defined as the elapsed time from the from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 49 months.","dispersionType":"95% Confidence Interval","groups":[{"description":"4mg RRx-001 once weekly (QW) until progression, followed by up to 6 cycles of platinum doublet chemotherapy","id":"OG000","title":"RRx-001 + Platinum Doublet (A01-09)"},{"description":"RRx-001 weekly for 3 weeks followed by up to 6 cycles of platinum doublet chemotherapy and then RRx-001 maintenance (for patients with stable disease (SD) or better at discontinuation of platinum).","id":"OG001","title":"RRx-001 + Platinum + RRx-001 (A10)"},{"description":"Standard of Care Investigator's Choice Control Arm, treatment options of one of the following: carboplatin, etoposide, doxil, gemcitabine, vinorelbine or taxane treatments until progression or intolerable toxicity","id":"OG002","title":"Investigator's Choice (A10)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Assessed up to 49 months","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}